We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis.
- Authors
Kozłowska, Dorota; Myśliwiec, Hanna; Harasim-Symbor, Ewa; Milewska, Anna Justyna; Chabowski, Adrian; Flisiak, Iwona
- Abstract
Fatty acid binding protein 5 (FABP5) is elevated in psoriatic keratinocytes and could be involved in systemic metabolic disturbances in psoriasis. The aim of the study was to evaluate serum FABP5 in obese and non-obese psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband—ultraviolet B (NB-UVB). Seventy-four patients (30 treated with NB-UVB) with psoriasis were enrolled in the study. The serum concentrations of FABP5 were measured using Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Serum fatty acids were measured by gas–liquid chromatography. Serum FABP5 levels in psoriatic patients were higher versus control group (P < 0.001). FABP5 in patients with PASI > 20 was higher compared to the mild group (PASI < 10) (P < 0.001) and serum FABP5 correlated positively with PASI score (r = 0.41, P < 0.001). There was also positive correlation between FABP5 and basic inflammation indices. Decrease of PASI after NB-UVB treatment (P < 0.001) was observed and accompanied by decrease of the serum FABP5 (P = 0.007). FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances in psoriatic patients.
- Subjects
CARRIER proteins; FATTY acids; BIOMARKERS; GAS chromatography; ENZYME-linked immunosorbent assay
- Publication
Molecular Biology Reports, 2021, Vol 48, Issue 5, p4421
- ISSN
0301-4851
- Publication type
Article
- DOI
10.1007/s11033-021-06461-3